Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. breached their fiduciary duties through potential self-dealing. This legal probe could lead to damages for shareholders and reforms in corporate governance. Long-term Immunovant investors are encouraged to contact the law firm for a free consultation to protect their rights. The investigation highlights concerns about management's integrity and shareholder value protection.
Viomi Technology announced it received a Nasdaq notice because its American Depositary Shares (ADS) closed below $1.00 for 30 consecutive business days, failing to meet Nasdaq's minimum bid price rule. The company has 180 days, until January 19, 2027...
On July 22, 2026, Shell plc purchased 75,000 of its own shares for cancellation at an average price of £33.04 per share on the London Stock Exchange. This transaction is part of Shell's previously announced share buy-back program initiated on May 7, ...
The global market for implantable cardiac fluorine-free resins is projected to grow from $1.52 billion in 2025 to $4.26 billion by 2035, at a compound annual growth rate of 10.8%. This growth is driven by rising cardiovascular disease rates, aging po...
Wolters Kluwer repurchased 107,794 of its ordinary shares between July 16 and July 22, 2026, spending €6.6 million at an average price of €61.23 per share. This buyback is part of a larger 2026 program aiming to repurchase up to €500 million worth of...
Penske Automotive Group announced a quarterly dividend increase to $1.44 per share, up $0.02 or 1.4%, making the annual dividend $5.76 per share. This marks the company's 23rd consecutive quarterly dividend increase, reflecting strong business perfor...
